Multiple Myeloma | Clinical

Rationale Taken From Trial Data for Using Daratumumab in Multiple Myeloma

January 19, 2021

During a Targeted Oncology Case-Based Peer Perspectives Roundtable event, Alex Mejia-Garcia, MD, medical oncologist, Cleveland Clinic, discussed the use of daratumumab as treatment of multiple myeloma. The discussion was based on the case scenario of a 51-year-old patient.

Analysis Explores Impact of Increased Point Mutations With High-Dose Melphalan in Myeloma

December 28, 2020

Mehmet K. Samur, PhD, discusses findings from an analysis evaluating high-dose melphalan followed by autologous stem cell transplant as treatment of patients with multiple myeloma compared with the standard of care treatment regimen lenalidomide, bortezomib, and dexamethasone alone.